Aegea Medical is beginning a post-market study to evaluate the effects of its Adaptive Vapor Ablation technology in endometrial ablation procedures for three to four years post-treatment. The study will include up to 50 women who previously participated in the pivotal trial and will assess uterine cavity access and the feasibility of diagnostic and therapeutic interventions.
Aegea begins post-market endometrial ablation tech study
Sign up for uPdaTe SmartBrief
News for physical therapists focused on women's health
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.